Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 651 to 675 of 881

TitleReference numberPublishedLast updated
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Nivolumab for previously treated advanced renal cell carcinomaTA417
Dapagliflozin in triple therapy for treating type 2 diabetesTA418
Apremilast for treating moderate to severe plaque psoriasisTA419
Dapagliflozin in combination therapy for treating type 2 diabetesTA288
Elbasvir–grazoprevir for treating chronic hepatitis CTA413
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Secukinumab for treating active ankylosing spondylitisTA407
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400

Results per page

  1. 10
  2. 25
  3. 50
  4. All